Research Site

Elmhurst, Illinois 60126

1 studies enrolling now · 11 studies all time

What they study most

Bone Pain in Stage I - III Breast Cancer, Breast Cancer, Breast Cancer, Early Breast Cancer, Carcinoma, Carcinoma, Non-Small-Cell Lung, Diabetes Mellitus, Type 2, Metastases, Neoplasm, Non-Small Cell Lung Cancer, Non-small-cell Lung, Relapsing Multiple Sclerosis, Viral Lung Infection and Acute Respiratory Failure

Studies at this site

• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen — Recruiting now
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) — Recruiting now
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC — Recruiting now
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation — Running, not enrolling
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer — Running, not enrolling
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
• NOLAN: Naproxen or Loratadine and Neulasta — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Iressa Expanded Access Program (EAP) — Completed